Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724048 · ClinicalTrials.gov registry record · Phase 2
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
A Phase 2 study of Huntington Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
- 20
- Study locations
NCT00724048: Completed Phase 2 study of Huntington Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT00724048 is a Phase 2 study of Huntington Disease that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 227 participants, below the 629-participant average among 35 other Huntington Disease trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00724048, a Phase 2 study of Huntington Disease, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.
Primary Outcome
The mMS is a subscale of the UHDRS total motor score and comprises 13 responses from the 10 items, 4-10 and 13-15, from the UHDRS motor assessment. The items for mMS included dysarthria, tongue protrusion, finger taps (right and left), pronate/supinate hands (right and left), luria - first-hand-palm sequencing, arms rigidity (right and left), body bradykinesia, gait, tandem walking, and retropulsion pull test. Each of these items were rated on a scale of 0 (normal) to 4 (marked impairment). Tota
Conditions Studied
Interventions
- OTHER Placebo
- DRUG ACR16
Study Locations (20)
New York
- Albany Medical College - Albany
- North Shore-LIJ Health System - Manhasset
- University of Rochester - Rochester
Maryland
- University of Maryland School of Medicine - Baltimore
- Johns Hopkins University - Baltimore
Ohio
- University of Cincinnati - Cincinnati
- Ohio State University Parkinson's Center - Columbus
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California - San Diego
Colorado
- Colorado Neurological Institute - Littleton
Florida
- University of South Florida - Tampa
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2008-10-24 |
| Est. Completion | 2010-07-26 |
| Phase | Phase 2 |
What the finished NCT00724048 record still lists
NCT00724048 is an interventional study that assigns participants to a tested intervention. The registered 227 participants enrollment target is mid-sized for trials with a published cap, below the 629-participant average among 35 other Huntington Disease trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00724048 names 20 study sites across 16 states, led by New York, Maryland, Ohio.
Frequently Asked Questions
What is clinical trial NCT00724048 about?
NCT00724048 is a clinical study titled "A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease". The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.
What is the current status of trial NCT00724048?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2008-10-24. Estimated completion is 2010-07-26.
What conditions does trial NCT00724048 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT00724048?
The interventions under investigation include: Placebo (OTHER), ACR16 (DRUG).
Who is sponsoring clinical trial NCT00724048?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00724048 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00724048's enrollment target sits among peer trials
227 14th of 35 higher than 22 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
ACTIVE NOT RECRUITING · Phase 2
-
Creatine Safety and Tolerability in Premanifest HD: PRECREST
COMPLETED · Phase 2
-
Atomoxetine and Huntington's Disease
COMPLETED · Phase 2
-
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
COMPLETED · Phase 2
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04751409 · 227 participants · Phase 2
Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities
- NCT05742360 · 227 participants
Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype
- NCT05890352 · 227 participants · Phase 2
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI